Following the decision to discontinue the development of Danuglipron due to safety concerns, Pfizer ( PFE ) announced its interest in pursuing business development opportunities seeking to acquire promising product candidates in theOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the p ...